Nanomedicines — typically drugs hidden within nanoscopic fatty membranes (‘liposomes’) — have potential to transform chemotherapy treatments, improving drug delivery and reducing toxic side effects for thousands of cancer patients every year.
Now, world first research conducted by the University of South Australia has identified that the frequently used chemotherapy drug (5-FU or Fluorouracil) is 100 per cent more effective at targeting tumours (rather than surrounding tissues) when administered using an optimised liposomal formulation.
